insufficient recuritment due to covid

This study will evaluate the effectiveness of aflibercept (Eylea®) using two different treatment protocols in patients with vision loss from diabetic macular edema. While one group will be treated with an optical coherence tomography (OCT) guided 'treat and extend' regimen, the other group will be treated according to a visual acuity (VA) guided 'treat and extend' protocol. The patients will be randomized into two treatment arms using an automated randomization algorithm.

For the study arm receiving the VA-guided treatment regimen, the following retreatment criteria will be applied:

• if visual acuity remains stable (± 5 ETDRS letters) treatment intervals will be extended by 2 weeks as compared to the previous retreatment interval.
• if visual acuity decreases by more than 5 ETDRS letters treatment intervals will be shortened by 1 week as compared to the previous retreatment interval, whereby retreatment intervals cannot be shorter than 28 days (4 weeks). Once treatment intervals have been shortened, the patient should be seen at two consecutive visits with no diabetic retinopathy disease activity before re-extending the treatment interval.

For the study arm receiving the OCT-guided treatment regimen, the following retreatment criteria will be applied:

• if SD-OCT examinations show 1) no SRF in any area of the OCT scan present and 2) no IRF, treatment intervals will be extended by 2 weeks as compared to the previous retreatment interval.
• if SD-OCT examinations show 1) any SRF present in any area of the OCT scan and/or 2) any IRF present, treatment intervals will be shortened by 1 week as compared to the previous retreatment interval, whereby retreatment intervals cannot be shorter than 28 days (4 weeks). Once treatment intervals have been shortened, the patient should be seen at two consecutive visits with no diabetic retinopathy disease activity before re-extending the treatment interval.

General:

• Informed consent as documented by signature of the patient on the informed consent form.
• Male or female, ≥ 18 years of age.
• Patients with Type 1 or Type 2 diabetes mellitus (according to ADA or WHO guidelines).
• No relevant change in medication for the management of diabetes within 3 months prior to randomization.
• Patients fulfilling criteria specified in the respective SmPC for aflibercept for the treatment of DME

Study eye:

• Visual impairment due to focal or diffuse DME in at least one eye. If both eyes are eligible, the eye with the worse visual acuity, as assessed at Visit 1, will be selected for study treatment unless, based on medical reasons, the investigator deems the other eye the more appropriate candidate for study treatment.
• BCVA score between 78 and 39 letters using ETDRS- visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160) Decrease in vision and CRT due to DME and not due to other causes, at the investigators discretion

Inclusion criteria:

General:

• Informed consent as documented by signature of the patient on the informed consent form.
• Male or female, ≥ 18 years of age.
• Patients with Type 1 or Type 2 diabetes mellitus (according to ADA or WHO guidelines).
• No relevant change in medication for the management of diabetes within 3 months prior to randomization.
• Patients fulfilling criteria specified in the respective SmPC for aflibercept for the treatment of DME

Study eye:

• Visual impairment due to focal or diffuse DME in at least one eye. If both eyes are eligible, the eye with the worse visual acuity, as assessed at Visit 1, will be selected for study treatment unless, based on medical reasons, the investigator deems the other eye the more appropriate candidate for study treatment.
• BCVA score between 78 and 39 letters using ETDRS- visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160) Decrease in vision and CRT due to DME and not due to other causes, at the investigators discretion

Exclusion criteria:

General:

• Inability to comply with study or follow-up procedures.
• Pregnant or nursing (lactating) women.
• Women of child-bearing potential, not using or not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the Investigator in individual cases.(Female participants who are surgically sterilised/ hysterectomised, or post-menopausal for longer than 2 years are not considered as being of child-bearing potential.)
• Any type of systemic disease or its treatment, in the opinion of the Investigator, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree.
• Stroke or myocardial infarction less than 3 months prior to the date of informed consent signature.
• Known hypersensitivity to aflibercept or any component of the aflibercept formulation. Any other reason that would prevent treatment with aflibercept specified in the SmPC
• Current use of any systemic anti- VEGF drugs [e.g., bevacizumab (Avastin®)].
• Use of other investigational drugs at screening visit.

Both eyes:

• Any active ocular infection or inflammation (scleritis, uveitis, endophthalmitis) at the time of screening or baseline.
• Uncontrolled glaucoma [intraocular pressure (IOP) ≥30 mmHg on medication or according to Investigator's judgment] at the time of screening or baseline.
• Neovascularisation of the iris or neovascular glaucoma at the time of screening or baseline.
• Intravitreal corticosteroids administered within 3 months prior to the date of informed consent signature.

Study eye:

• Visually significant cataract, vitreous hemorrhage, rhegmatogenous retinal detachment or age related macular degeneration
• Intraocular treatment with any anti-VEGF drug or intravitreal corticosteroids prior to the date of informed consent signature.
• Inability of obtaining SD-OCT images of sufficient quality to be analysed
• Any intraocular procedure anticipated within the next 6 months following the date of informed consent signature

Patients with vision loss due to diabetic macular edema